The aim of this randomized double blind control trial was to validate the safety and efficacy of 6 months vs. 12 months clopidogrel treatment in patients receiving DES. Primary end point was a combination of death, infarction, in-stent thrombosis, stroke and major bleeding. Secondary end point was the individual analysis of each one of the<a href="https://solaci.org/en/2015/06/24/isar-safe-6-vs-12-month-clopidogrel-administration-after-des-implantation/" title="Read more" >...</a>
Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post DES stenting. 9961 patients were randomized to continue on placebo or thienopyridine after 12 months. Thienopyridine reduces the incidence of in-stent thrombosis (0.4% vs 1.4%; p<0,001) and cardiovascular events (4.3%<a href="https://solaci.org/en/2015/06/24/dapt-trial-double-antiaggregation-remains-controversial/" title="Read more" >...</a>
Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy after confirming non-resistance to aspirin. Primary end point was a combination of death, infarction, emergency revascularization of target vessel, stroke and major bleeding. The study saw early termination due to<a href="https://solaci.org/en/2015/06/24/italic-plus-6-months-of-double-antiaggregation-for-no-less-than-24-months/" title="Read more" >...</a>
This multicenter study randomized 1063 patients to receive the sirolimus-eluting stent with absorbable polymer and 1056 patients to permanent polymer stent. No differences in stent thrombosis (3.4% in the group with permanent polymer versus 2.8% in the group with absorbable polymer), target vessel revascularization (6.7% for both) or mortality (2.1% versus 2.9%; p = 0.7).<a href="https://solaci.org/en/2015/06/24/bioscience-study-absorbable-polymer-versus-permanent-in-sirolimus-eluting-stents/" title="Read more" >...</a>
The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an ST-segment elevation acute myocardial infarction. Pre-hospital management that could improve coronary reperfusion and events like death or stent thrombosis was not studied. 1862 patients were included suffering ST-segment elevation acute myocardial<a href="https://solaci.org/en/2015/06/24/atlantic-administration-of-ticagrelor-in-the-ambulance-versus-in-the-cath-lab/" title="Read more" >...</a>
The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a problem not yet solved same for all drug-eluting stents. The Absorb (Abbott Vascular, Abbott Park, IL, USA) is the first absorbable vascular support approved for clinical use. The EVERBIO II study<a href="https://solaci.org/en/2015/06/24/everbio-ii-bio-absorbable-stent-absorb-versus-everolimus-eluting-or-biolimus-stents/" title="Read more" >...</a>
This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus 1 year (n = 717) dual anti-aggregation after implantation of 2nd generation drug-eluting stent. The primary end point was a composite of cardiac death, myocardial infarction, stroke, definite or probable thrombosis, and major bleeding. At 12 months follow-up<a href="https://solaci.org/en/2015/06/24/security-6-months-versus-12-months-of-dual-anti-aggregation-using-2nd-generation-des/" title="Read more" >...</a>
Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute coronary syndrome, especially if the patient has received coronary angioplasty. Few data are available in the real world in terms of safety and efficacy of prasugrel versus clopidogrel in this clinical context. This registry involved 12227 patients undergoing<a href="https://solaci.org/en/2015/06/24/translate-acs-one-year-prasugrel-versus-clopidogrel-after-acute-coronary-syndrome/" title="Read more" >...</a>
There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and given the large surface area of the bowel may cause rapid hypothermia reducing infarct size. The aim of this study was to evaluate the safety and efficacy of hypothermia induced by<a href="https://solaci.org/en/2015/06/24/velocity-peritoneal-hypothermia-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>
The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB / IIIA glycoprotein in reducing adverse clinical events in patients suffering an ST-segment elevation myocardial infarction undergoing primary angioplasty, at the expense of increase in the rate of acute stent thrombosis. This study included 2194 patients undergoing an<a href="https://solaci.org/en/2015/06/24/bright-bivalirudin-versus-heparin-versus-heparin-plus-tirofiban-in-primary-angioplasty/" title="Read more" >...</a>